High USP22 expression indicates poor prognosis in hepatocellular carcinoma

Oncotarget

Volumn 6, Issue 14, 2015, Pages 12654-12667

  Tang, Bo ^a,b   Tang, Fang ^a   Li, Bo ^a,b   Yuan, Shengguang ^a,b   Xu, Qing ^a,b   Tomlinson, Stephen ^c   Jin, Junfei ^b   Hu, Wei ^d   He, Songqing ^a,b  

^a GUILIN MEDICAL UNIVERSITY   (China)

^b Molecular Medicine in Liver Injury and Repair   (China)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d JILIN UNIVERSITY   (China)

Author keywords

Cancer biomarker; Hepatocellular carcinoma; Prognosis; Ubiquitin specific protease 22

Indexed keywords

CASPASE 3; CYTOCHROME C; DEUBIQUITINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN USP22; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; THIOL ESTER HYDROLASE; TUMOR MARKER; USP22 PROTEIN, HUMAN;

ADULT; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; OVERALL SURVIVAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; BIOSYNTHESIS; DISEASE FREE SURVIVAL; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; WESTERN BLOTTING;

ADULT; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; THIOLESTER HYDROLASES;

EID: 84930014159     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3705     Document Type: Article

References (25)

1. Parkin, DM, Bray, F, Ferlay J, Pisani P. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Bosch FX, Ribes J, Díaz M, Cléries R.Primary liver cancer: worldwide incidence and trends. Gastroenterology.2004;127: S5-S16.
3. Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM, Baek KH. The expression patatterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr Patterns. 2006;6: 277-284.
4. Zhang XY1, Varthi M, Sykes SM, Phillips C, Warzecha C, Zhu W, Wyce A, Thorne AW, Berger SL, McMahon SB. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell. 2008;29: 102-111.
5. Zhang XY, Pfeiffer HK, Thorne AW, McMahon, SB. USP22, anhSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle. 2008;7: 1522-1524.
6. Atanassov BS, Dent SY. USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep. 2011;12: 924-930.
7. Liu Y, Yang Y, Xu H, Dong X. Implication of USP22 in the regulation of BMI-1, c-Myc, P16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinomas. Diagn Mol Pathol. 2010;19: 194-200.
8. Zhang Y, Yao L, Zhang X, Ji H, Wang L, Sun S, Pang D. Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J Cancer Res Clin Oncol. 2011;137: 1245-1253.
9. Yang DD1, Cui BB, Sun LY, Zheng HQ, Huang Q, Tong JX, Zhang QF. The co-expresion of USP22 an BMI-1 may promote cancer progression and predict therapy failure in gastric carcinoma. Cell Biochem Biophys. 2011; 61: 703-710.
10. Llovet J M, Brú C, Bruix J. (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338.
11. Xu Y1, Liu L, Liu J, Zhang Y, Zhu J, Chen J, Liu S, Liu Z, Shi H, Shen H, Hu Z. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. International Journal of Cancer. 2011;128: 412-417.
12. Baldissera VD, de Mattos AA, Coral GP, de Araujo FB, Marroni CA, de Mello Brandão AB, Ott Fontes PR, Schmidt Cerski CT, Hartmann AA, Kretzmann Filho NA. Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma. Ann Hepatol. 2012;11: 899-906.
13. Gao Q, Zhao YJ, Wang XY, Qiu SJ, Shi YH, Sun J, Yi Y, Shi JY, Shi GM, Ding ZB, Xiao YS, Zhao ZH, Zhou J, et al. CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Res. 2012 ;72: 3546-3556.
14. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, et al. Gene expression in fixed tissues and outcome 14.in hepatocellular carcinoma. N Engl J Med. 2008;359: 1995-2004.
15. Piao S, Ma J, Wang W, Liu Y, Zhang M, Chen H, Guo F, Zhang B, Guo F. Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma. Oral Oncol. 2013;49: 796-801.
16. Ning J, Zhang J, Liu W, Lang Y, Lang Y, Xue Y, Xu S. Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer. Eur J Histochem. 2012;56: e46.
17. Piao S, Liu Y, Hu J, Guo F, Ma J, Sun Y, Zhang B. USP22 is useful as a novel molecular marker for predicting disease progression and patient prognosis of oral squamous cell carcinoma. PloS One. 2012;7: e42540.
18. Liu Y L, Yang Y M, Xu H, Dong XS. Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer. J Gastroenterol Hepatol. 2010;25: 1800-1805.
19. Zhang XY, Harla K, Pfeiffer, Alan W, Thorne, Steven B McMahon. (2008) USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histon H2A. Cell Cycle 7:11, 1522-1524.
20. Liu YL, Jiang SX, Yang YM, XU H, Lui JL, Wang XS. (2012) USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem Biophys 62:229-235.
21. Liu YL1, Jiang SX, Yang YM, Xu H, Liu JL, Wang XS. USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem Biophys. 2011;62: 229-235.
22. Liang J, Yu Y, Wang B, Lu B, Zhang J, Zhang H, Ge P. Ginsenoside Rb1 attenuates oxygen-glucose deprivationinduced apoptosis in SH-SY5Y cells via protection of mitochondrial and inhibition of AIF and cytochrome c release. Molecules. 2013;18: 12777-92.
23. Li J, Wang Z, Li Y. USP22 nuclear expression is significantly associated with progression and unfavorable clinical outcome in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2012;138: 1291-1297.
24. Cheng AL, Huang WG, Chen ZC, Peng F, Zhang PF, Li MY, Li F, Li JL, Li C, Yi H, Yi B, Xiao ZQ. Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis. Clin Cancer Res. 2008;14: 435-445.
25. Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol. 2007;60: 1112-1116.